NCT03059849 (BEAT-IBD) is a Phase 4 clinical trial of Adalimumab in Crohn Disease, sponsored by McMaster University.

Who is sponsoring NCT03059849?

NCT03059849 is sponsored by McMaster University.

What drugs are being tested in NCT03059849?

Interventions in NCT03059849: Adalimumab.

What condition does NCT03059849 study?

NCT03059849 studies Crohn Disease, Ulcerative Colitis.

Is NCT03059849 still recruiting?

NCT03059849 is currently withdrawn. Last updated 18 January 2020.

Last reviewed 2020-01-18 · How we verify

NCT03059849: BEAT-IBD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD

Withdrawn Phase 4 Last updated 18 January 2020

What this trial tests

Phase 4 trial testing Adalimumab in Crohn Disease. Withdrawn.

Timeline

1 February 2018

Primary endpoint
1 February 2019

1 September 2019

Quick facts

Lead sponsor	McMaster University
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 February 2018
Primary completion	1 February 2019
Estimated completion	1 September 2019

Drugs / interventions tested

Adalimumab (ADALIMUMAB) — full drug profile →

Conditions studied

Crohn Disease — all drugs for Crohn Disease →
Ulcerative Colitis — all drugs for Ulcerative Colitis →

Sponsor

McMaster University

Who can join

Adults 18 to 80, any sex, with Crohn Disease or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To examine whether a temporary three month increase in adalimumab dosing will prevent relapse in patients with inflammatory bowel disease in clinical remission who have elevated calprotectin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Adalimumab

Trials testing the same drug.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT07268534 — Biologics in Folliculitis Decalvans : an Adaptative Trial Research · Phase 2 · not yet recruiting
NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting

Other McMaster University trials

Trials by the same sponsor.

NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
NCT07486505 — Mindfulness in Fracture Recovery and Reduction of Opioid Reliance: Evaluating the Feasibility of Implementing a Brief, M · NA · not yet recruiting
NCT07408128 — Partner4Exercise Randomized Controlled Trial · Phase 2, PHASE3 · not yet recruiting
NCT07459777 — Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anteri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03059849 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by McMaster University
Last refreshed: 18 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03059849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing